BEYOND THE ANTICIPATED: “MONTELUKAST AND DELIRIUM” – A CASE REPORT
Breezy Ani Sam*, Nayana Rachel Koshy and Dr. Sara Kurien K., Dr Jaico Paulose
ABSTRACT
Montelukast is a leukotriene receptor antagonist (LTRA) that, in contrast to other airway receptors such as prostanoid, cholinergic, or beta-adrenergic receptors, exclusively targets cysteinyl leukotriene receptor type-1 by preventing LTD4 mediated bronchoconstriction with dosages as low as 5 mg. Behavioral alterations with Montelukast administration have been shown in several human trials. Psychotic symptoms, such as hallucinations, insomnia, nightmares, anxiety, aggressiveness and headache are seen in adults and children after taking medicine and stop when Montelukast therapy is withdrawn. We discuss one such instance of Montelukast induced delirium.
Keywords: Montelukast, Leukotriene receptor antagonist, Delirium, Neuropsychiatric adverse effects.
[Full Text Article]
[Download Certificate]